Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Deffered Revenue (2024 - 2025)

Historic Non-Current Deffered Revenue for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to $268.9 million.

  • Kura Oncology's Non-Current Deffered Revenue changed N/A to $268.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.9 million, marking a year-over-year change of. This contributed to the annual value of $253.9 million for FY2024, which is N/A changed from last year.
  • Per Kura Oncology's latest filing, its Non-Current Deffered Revenue stood at $268.9 million for Q3 2025.
  • Kura Oncology's Non-Current Deffered Revenue's 5-year high stood at $271.9 million during Q1 2025, with a 5-year trough of $252.5 million in Q2 2025.